Reversibility of the monocrotaline pulmonary hypertension rat model

European Respiratory Journal

Volumn 42, Issue 2, 2013, Pages 553-556

  Ruiter, Gerrina ^a   De Man, Frances S ^a   Schalij, Ingrid ^a   Sairras, Shellice ^a   Grúnberg, Katrien ^a   Westerhof, Nico ^a   Van Der Laarse, Willem J ^a   Vonk Noordegraaf, Anton ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCROTALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; ECHOCARDIOGRAPHY; HEART INDEX; HEART MUSCLE FIBROSIS; HEART RATE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART STROKE VOLUME; HEMODYNAMICS; HISTOPATHOLOGY; LETTER; LIVER WEIGHT; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION;

ANIMALS; ARTERIOLES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; HEMODYNAMICS; HYPERTENSION, PULMONARY; LIVER; MALE; MONOCROTALINE; PULMONARY ARTERY; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 84882684793     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00012313     Document Type: Letter

References (13)

1. Stenmark KR, Meyrick B, Galie N, et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1013-L1032.
2. Huxtable RJ. Activation and pulmonary toxicity of pyrrolizidine alkaloids. Pharmacol Ther 1990; 47: 371-389.
3. Campian ME, Hardziyenka M, Michel MC, et al. How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 391-400.
4. Gomez-Arroyo JG, Farkas L, Alhussaini AA, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 2012; 302: L363-L369.
5. Lee YS, Byun J, Kim JA, et al. Monocrotaline-induced pulmonary hypertension correlates with upregulation of connective tissue growth factor expression in the lung. Exp Mol Med 2005; 37: 27-35.
6. Firth AL, Mandel J, Yuan JX. Idiopathic pulmonary arterial hypertension. Dis Model Mech 2010; 3: 268-273.
7. Hessel MH, Steendijk P, den Adel B, et al. Characterization of right ventricular function after monocrotalineinduced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol 2006; 291: H2424-H2430.
8. Handoko ML, de Man FS, Happé CM, et al. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 2009; 120: 42-49.
9. Ryan J, Bloch K, Archer SL. Rodent models of pulmonary hypertension: harmonisation with the world health organisation?s categorisation of human PH. Int J Clin Pract Suppl 2011; 172: 15-34.
10. Jones JE, Mendes L, Rudd MA, et al. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol 2002; 283: H364-H371.
11. Hardziyenka M, Campian ME, de Bruin-Bon HA, et al. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiogr 2006; 19: 1272-1279.
12. de Man FS, Handoko ML, van Ballegoij JJ, et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 2012; 5: 97-105.
13. Roth RA, Dotzlaf LA, Baranyi B, et al. Effect of monocrotaline ingestion on liver, kidney, and lung of rats. Toxicol Appl Pharmacol 1981; 60: 193-203.